Latest Endo Pharmaceuticals Stories
CHADDS FORD, Pa., May 25, 2012 /PRNewswire/ -- Endo Health Solutions Inc. (Nasdaq: ENDP) today announced that Julie McHugh, chief operating officer, will present a corporate overview at the Jefferies 2012 Global Healthcare Conference on Monday, June 4, 2012 at 9:00 a.m. ET. The conference will be held in New York City. A live webcast and audio archive of the presentation will be available on the company's website at http://www.endo.com/. Click on Investor Relations, and then the...
CHADDS FORD, Pa., May 23, 2012 /PRNewswire-FirstCall/ -- Shareholders of Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP) voted today at its annual shareholders meeting to approve changing the company's name to Endo Health Solutions Inc. The name change is in conjunction with the launch of Endo's new corporate identity and more accurately reflects the company's new business model. Endo Health Solutions has aggregated four operating businesses into one enterprise aimed at...
RALEIGH, N.C., May 9, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the Bank of America Merrill Lynch Healthcare Conference at Encore at the Wynn Hotel, Las Vegas, Nevada. The presentation is scheduled for Thursday, May 17, 2012 at 11:20 A.M. Pacific Time (2:20 P.M. Eastern Time). (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO) Dr. Sirgo...
CHADDS FORD, Pa., May 4, 2012 /PRNewswire/ -- Endo (Nasdaq: ENDP) today announced that Alan Levin, executive vice president and chief financial officer, will present a corporate overview at the Bank of America Merrill Lynch 2012 Heath Care Conference on Wednesday, May 16, 2012 at 12:20 p.m. ET. The conference will be held at the Encore at Wynn Hotel in Las Vegas. A live webcast and audio archive of the presentation will be available on the company's website at http://www.endo.com/....
CHADDS FORD, Pa., May 1, 2012 /PRNewswire/ -- Total quarterly revenues of $691 million, increased 23 percent versus prior year; Driven by full quarter addition of AMS as well as Qualitest revenue growth of 8 percent. Adjusted diluted EPS of $0.87, aligned with prior guidance of below $0.90. Reported quarterly diluted loss per share of $0.75 versus earnings per share of $0.46 for prior year. Management expects return to year-over-year adjusted diluted earnings growth for...
CHADDS FORD, Pa., April 17, 2012 /PRNewswire/ -- Endo Pharmaceuticals Holdings (Nasdaq: ENDP) will announce its first quarter 2012 financial results on May 1, 2012 and will host a conference call and webcast at 8:30 a.m. ET that day to discuss these results. David P. Holveck, president and CEO of Endo, Julie McHugh, chief operating officer, Dr. Ivan Gergel, executive vice president of R&D, Alan Levin, executive vice president and chief financial officer, and Blaine Davis, senior...
RALEIGH, N.C., April 17, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that the U.S. Patent and Trademark Office (USPTO) has formally awarded BDSI's patent No. 13/184306, "Transmucosal Delivery Devices with Enhanced Uptake," which extends the patent protection for BDSI's BioErodible MucoAdhesive (BEMA) products, BEMA Buprenorphine and BEMA Buprenorphine/Naloxone, by seven years to 2027. The USPTO had issued a Notice of Allowance to BDSI for...
RALEIGH, N.C., April 16, 2012 /PRNewswire/-- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the Future Leaders in the Biotech Industry Conference at the Millennium Broadway Hotel & Conference Center, New York City. The presentation is scheduled for Friday, April 20, 2012 at 3:00 P.M. Eastern Time. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO) Dr. Sirgo...
HUNTSVILLE, Ala., April 12, 2012 /PRNewswire-FirstCall/ -- Qualitest Pharmaceuticals today announced that the U.S. Food and Drug Administration has approved Levetiracetam Oral Solution, 100mg/mL. Qualitest plans to begin distribution in mid-2012. The total sales for Levetiracetam Oral Solution, 100mg/mL, in the U.S. for the 12 months ending Dec. 31, 2011, were approximately $62.2 million, according to IMS Health. About Qualitest Founded in 1983, Qualitest provides affordable,...
CHICAGO, April 10, 2012 /PRNewswire/ -- Seven Summits Research issues critical PriceWatch Alerts for SINA, CF, AOL, NWSA, and ENDP. To see what our analysts have discovered about these stocks read the Seven Summits Strategic Investments' PriceWatch Alerts at http://www.iotogo.com/s/041012B (Note: You may have to copy this link into your browser then press the [ENTER] key.) Today's PriceWatch Alerts cover the following stocks: Sina (Nasdaq: SINA), CF Industries (NYSE: CF), AOL (NYSE:...
